UR Biologie Moléculaire des leucémies et lymphomes, Faculté de Médecine de Sousse, Université de Sousse, Tunisia.
Leuk Res. 2012 Mar;36(3):316-23. doi: 10.1016/j.leukres.2011.11.002. Epub 2011 Nov 29.
FLT3 internal tandem duplication (FLT3-ITD) is usually considered as a bad marker for minimal residual disease (MRD) follow-up in acute myeloid leukemia (AML). Our objective was to evaluate the suitability of FLT3-ITD as a target for MRD detection by real-time quantitative PCR, in comparison with two other molecular MRD markers, NPM1 mutation and WT1 overexpression, in 20 adult AML patients treated in Acute Leukemia French Association (ALFA) trials. Overall, these 3 MRD markers showed comparable kinetics in 17/20 (85%) cases. Furthermore, we found that FLT3-ITD MRD levels after induction chemotherapy are predictive of complete remission duration.
FLT3 内部串联重复（FLT3-ITD）通常被认为是急性髓系白血病（AML）微小残留病（MRD）随访的不良标志物。我们的目的是通过实时定量 PCR 评估 FLT3-ITD 作为 MRD 检测靶点的适用性，并与 NPM1 突变和 WT1 过表达这两种其他分子 MRD 标志物进行比较，在 20 例接受急性白血病法国协会（ALFA）试验治疗的成人 AML 患者中进行。总体而言，这 3 种 MRD 标志物在 17/20（85%）例中显示出相似的动力学。此外，我们发现诱导化疗后 FLT3-ITD MRD 水平可预测完全缓解持续时间。
